secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001023024-26-000005
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharma 2025 rev ~$854-873M, Cortrophin Gel up 76% YoY; 2026 rev target $1.06-1.12B
--------------------------------------------------------------------------------

- Full-year 2025 total net revenues expected within or above $854M-$873M guidance ( ~39% YoY growth).
- Cortrophin Gel net rev $347.8M in 2025 (+76% YoY); Q4 Cortrophin Gel $111.4M (+88% YoY).
- 2026 guidance: total net rev $1,055M-$1,115M, Cortrophin Gel $540M-$575M, adj EBITDA $275M-$290M, adj EPS $8.83-$9.34.
- Plans to expand Rare Disease sales force by ~90 in mid-2026 to target acute gouty arthritis flares.
- Unrestricted cash $285M at Dec 31, 2025; ILUVIEN+YUTIQ combined rev $74.9M in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302426000005/0001023024-26-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302426000005/ani-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001023024-26-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer